Member Info for MaverickD

Its taken the sells now for the buys......under 30 and the NAV value here is 40p, so will see the algos buying

Director buy was at this level...….should see a bounce

Completed......the bounce to 50 should be on

Will take comfort in the results JD have posted - the carry over is that this is simply a blip and that things will improve. Three months leading to xmas is a busy period, I do believe a strong bounce inevitable from these levels.

They were after hours trades, buyers paid a premium to the close price - not delayed reported trades.

"Frequently, the number of patients treated in a MAP is significantly higher than the number of overall patients treated in the clinical trials for that medicine. These programmes therefore offer a unique opportunity to collect real-world data before launch, providing evidence to support the product's effectiveness, safety and value."

"We have received reports of data from MAPs being used to assist in demonstrating product value as supportive data in health technology assessments"

I believe that we have a major pharma that is interested and has suggested the MAP as a quick way to engage with a larger cohort.

Yesterday was an opportunity to buy cheap and the MMs took out some naughty stops on the back of the tripe The Times wrote. At the bell there were buy orders totalling almost a 1m broken down into 3 significant purchases that the MMs filled over the course of the day.

You have the update and this should be with us tomorrow with a little "reassurance" I am fully invested now.......

Lisa said nothing to be worried about.......lets see the news

Buy just filled

Normally, patients have to wait until regulators have approved a drug before they get access to it, but up to 500 lupus sufferers will receive Lupuzor as part of a Managed Access Programme

The drug works......that's for sure.....hence the managed access

Top pharma are interested, the drug works and we can see that across the studies...…...expecting a sharp bounce

They will be coming out all blazing. Investor relations will be key and to reassure the market. There is another RNS to land I am sure

Bagged some at under 15

Just taking the AT trades - stops went this morning

Orders filled - they wanted is cheaper and mopped up the stock expect a strong bounce

Should now see this climb back over 20p........the gaps filled and close of play should have us around 22

Just a shake to free up shares, fill orders and fill the gap - bounce back up, mark my words

Sense returns and one other factor I should point out is the fact that 63.01% of Footasylum shares are not in public hands. These are owned by the family members of the founders, which includes Clare Nesbitt, the CEO.

You therefore see that the free float is small so any scramble for shares, which we will see will cause the sp to advance and the correction will be pretty swift. 55p for me is a certainty, but could go a lot higher as anyone crazy to have shorted yesterday will be looking to close.

Wrong.....they have acknowledged success, they are extending the trials to a larger cohort. These shares will eventually be worth over £10 in my opinion and I am being conservative. They should bump along the 80p mark for sure, so that's why at these levels IMM is a steal.

Ureka divestment is something that highlights the expectations of the board with respect to Lupuzor and the signing of HOT with Incanthera.

Should see some money heading into IMM today.